Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
12.65 CAD | +46.24% | +25.37% | +94.62% |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
- The company has a poor ESG score according to Refinitiv, which ranks companies by sector.
Strengths
- The prospective high growth for the next fiscal years is among the main assets of the company
- Over the last twelve months, the sales forecast has been frequently revised upwards.
- Sales forecast by analysts have been recently revised upwards.
- For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
- The opinion of analysts covering the stock has improved over the past four months.
- Over the past twelve months, analysts' opinions have been strongly revised upwards.
Weaknesses
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- Low profitability weakens the company.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
- The company's earnings releases usually do not meet expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+94.62% | 346M | D+ | ||
+39.33% | 6.01B | B- | ||
-18.38% | 4.4B | C+ | ||
-9.17% | 3.17B | B- | ||
+3.98% | 3.07B | C | ||
-3.41% | 2.51B | - | D+ | |
+48.74% | 1.88B | - | ||
-4.82% | 1.73B | - | - | |
-1.24% | 1.65B | - | - | |
-8.96% | 1.58B | C- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- ACB Stock
- Ratings Aurora Cannabis Inc.